Skip to content
10-Q

Quarterly Report

BRAINSTORM CELL THERAPEUTICS INC. BCLI

0001410578-25-001347

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 11, 2025 7.94M sh
Short Term Debt Q1 2025 · Mar 31, 2025 $1.2M
Short Term Debt Q1 2025 · Dec 31, 2024 $300K
Cash And Equivalents Q1 2025 · Mar 31, 2025 $1.64M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $187K
Current Liabilities Q1 2025 · Mar 31, 2025 $10.9M
Current Liabilities Q1 2025 · Dec 31, 2024 $8.98M
Total Liabilities Q1 2025 · Mar 31, 2025 $11.03M
Total Liabilities Q1 2025 · Dec 31, 2024 $9.6M
Current Assets Q1 2025 · Mar 31, 2025 $2.33M
Current Assets Q1 2025 · Dec 31, 2024 $385K
Total Assets Q1 2025 · Mar 31, 2025 $3.57M
Total Assets Q1 2025 · Dec 31, 2024 $1.83M
Shares Diluted restated Q1 2025 · Mar 31, 2024 4.32M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$3.06M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$5.55M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$4.86M
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$0.75
Eps Basic restated Q1 2025 · Mar 31, 2024 −$0.75
Sga Expense Q1 2025 · Mar 31, 2024 $1.51M
Rd Expense Q1 2025 · Mar 31, 2024 $961K
Net Income Q1 2025 · Mar 31, 2024 −$3.4M
Operating Income Q1 2025 · Mar 31, 2024 −$2.47M